Last reviewed · How we verify
Rectalgan Mousse
Rectalgan Mousse is a topical rectal formulation that provides local anesthetic and anti-inflammatory effects for symptomatic relief of rectal pain and discomfort.
Rectalgan Mousse is a topical rectal formulation that provides local anesthetic and anti-inflammatory effects for symptomatic relief of rectal pain and discomfort. Used for Rectal pain and discomfort associated with hemorrhoids, anal fissures, and other rectal conditions.
At a glance
| Generic name | Rectalgan Mousse |
|---|---|
| Sponsor | University of Roma La Sapienza |
| Drug class | Topical rectal analgesic/anti-inflammatory |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
The mousse formulation delivers active pharmaceutical ingredients directly to the rectal mucosa, where they exert local anesthetic properties to reduce pain sensation and anti-inflammatory effects to decrease tissue inflammation. This localized delivery approach minimizes systemic absorption while providing targeted symptom relief in the rectal region.
Approved indications
- Rectal pain and discomfort associated with hemorrhoids, anal fissures, and other rectal conditions
Common side effects
- Local irritation or burning sensation
- Allergic contact dermatitis
- Transient stinging
Key clinical trials
- Pain and Bleeding in Subjects With Acute Anal Fissure: Comparative Evaluation of Three Treatments (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rectalgan Mousse CI brief — competitive landscape report
- Rectalgan Mousse updates RSS · CI watch RSS
- University of Roma La Sapienza portfolio CI